Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Sarepta Therapeutics
Pharmaceutical Preparation ManufacturingUnited StatesNASDAQ: SRPT
Last verified 23 days agosarepta.com
Sarepta Therapeutics, Inc., a leading player in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 1980, the company has made significant strides in developing innovative therapies for rare genetic diseases, particularly Duchenne muscular dystrophy (DMD). With a strong focus on gene therapy and precision medicine, Sarepta's core products, including its pioneering exon-skipping treatments, set it apart in the competitive landscape.
The company has achieved notable milestones, including the first FDA-approved gene therapy for DMD, solidifying its position as a market leader. Operating primarily in the US, Sarepta Therapeutics continues to expand its research and development efforts, aiming to transform the lives of patients with debilitating conditions through cutting-edge biopharmaceutical solutions.
25
DitchCarbon score
-17 vs industry average
Sarepta Therapeutics’s score of 25 is lower than 35% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sarepta Therapeutics?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2026
2020202120222023202420252026
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Sarepta Therapeutics's reported carbon emissions
Sarepta Therapeutics, a US-based pharmaceutical preparation manufacturer, reported its 2023 Scope 1 emissions at 3,428,000 kg CO2e and Scope 2 emissions at 5,000,000 kg CO2e. In 2022, its Scope 1 emissions were 2,701,000 kg CO2e and Scope 2 emissions were 4,789,000 kg CO2e. The company discloses Scope 1 and Scope 2 emissions but currently has no reported Scope 3 emissions data. Sarepta Therapeutics has not publicly disclosed any specific carbon reduction targets or commitments, such as Science Based Targets, nor has it signed up to initiatives like the Climate Pledge.
Assessing Sarepta Therapeutics as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Sarepta Therapeutics and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Sarepta Therapeutics’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Sarepta Therapeutics yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Sarepta Therapeutics23 days ago
25
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more